NASDAQ : ATYR
aTyr Pharma, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.95 USD (Nov 2, 2026, 9:01 AM EST) · Market cap 12.14M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 15.42M |
| Enterprise Value | -30.69M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.45M |
| Shares Outstanding | 2.45M |
| Shares Change (YoY) | +16.75% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 0.35% |
| Owned by Institutions (%) | 35.97% |
| Float | 2.44M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 63.76 |
| Forward PS | n/a |
| PB Ratio | 0.25 |
| P/TBV Ratio | 0.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.12 |
| Quick Ratio | 5.08 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -98.68% |
| Return on Assets (ROA) | -46.58% |
| Return on Invested Capital (ROIC) | -54.22% |
| Return on Capital Employed (ROCE) | -109.29% |
| Weighted Average Cost of Capital (WACC) | 4.80% |
| Revenue Per Employee | $3,167 |
| Profits Per Employee | -$1.01M |
| Employee Count | 60 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.91 |
| 52-Week Price Change | -81.84% |
| 50-Day Moving Average | 12.93 |
| 200-Day Moving Average | 24.08 |
| Relative Strength Index (RSI) | 31.76 |
| Average Volume (20 Days) | 83,523 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 10.27M |
| Short Previous Month | 12.89M |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.33 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 190,000 |
| Gross Profit | -46.90M |
| Operating Income | -63.86M |
| Pretax Income | -60.81M |
| Net Income | -60.81M |
| EBITDA | -63.20M |
| EBIT | -63.86M |
| Loss Per Share | -$24.86 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 57.42M |
| Total Debt | 11.30M |
| Net Cash | 46.12M |
| Net Cash Per Share | $18.81 |
| Equity (Book Value) | 48.59M |
| Book Value Per Share | 19.90 |
| Working Capital | 46.97M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -54.54M |
| Capital Expenditures | -279,000 |
| Depreciation & Amortization | 661,000 |
| Net Borrowing | -562,000 |
| Free Cash Flow | -54.82M |
| FCF Per Share | -$22.36 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -33,609.47% |
| Pretax Margin | -32,006.32% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -16.75% |
| Shareholder Yield | -16.75% |
| Earnings Yield | -395.16% |
| FCF Yield | -452.53% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $114.29 |
| Price Target Difference | 1,717.01% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 116.60% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 29, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -10.13 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |